Marker Therapeutics (MRKR) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

US Stock MarketDetailed Quotes

MRKR Marker Therapeutics

Watchlist

1.3800
-0.0700-4.83%

Close Mar 4 16:00 ET

14.78MMarket Cap-1.27P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
GlobeNewswireFeb 25 07:00 ET
Brookline Capital Initiates Marker Therapeutics(MRKR.US) With Buy Rating, Announces Target Price $4
Moomoo NewsFeb 10 18:31 ET · Ratings
Marker Therapeutics Initiated With a Buy at Brookline
TipRanksFeb 10 18:05 ET · Ratings
Life Sciences Stocks Fall on NIH Funding Concerns
Seeking AlphaJan 23 12:55 ET
Express News | Marker Therapeutics Inc Files for Resale of up to 10.1 Mln Shares by the Selling Stockholders - SEC Filing
ReutersJan 10 17:10 ET
Insider Purchase: 10% Owner at $MRKR (MRKR) Buys 554,250 Shares
Quiver QuantitativeDec 23, 2024 16:46 ET

Comments

Dec 19, 2024 07:11

Grrr! And this at same time as good news on data

$Marker Therapeutics (MRKR.US)$ Marker Therapeutics Announces $16.1 Million Private Placement

1

2

Dec 19, 2024 07:09

$Marker Therapeutics (MRKR.US)$ Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
3 MINUTES AGO, 8:05 AM EST
VIA GLOBENEWSWIRE
APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR)
MT-601 was observed to be well tolerated in all study participants with no observation of immune-effector cell associated neurotoxicity syndrome (ICANS)

2

Dec 17, 2024 06:36

$Marker Therapeutics (MRKR.US)$
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
Tuesday, 17th December at 7:00 am
HOUSTON, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and...

2

Green Dragon 2024

Nov 12, 2024 10:45

Thinking it’s time for data…

$Marker Therapeutics (MRKR.US)$ its been long enough for company to gather data and present. what do you say?

1

Oct 22, 2024 14:11

$Marker Therapeutics (MRKR.US)$

1

Read more